Original Publication Date: 1 February, 2015
Publication / Source: Clinical Investigation
Authors: Assunta Sgambato, Francesca Casaluce, Antonio Rossi et al
Targeted therapies based on molecular diagnostics have opened a new era of personalized medicine in lung cancer treatment. Recently, anaplastic lymphoma kinase (ALK) fusion gene emerged as an important biomarker for identifying a small proportion of non-small-cell lung cancer (NSCLC) patients that will benefit from ALK kinase inhibitor crizotinib, like EGFR activating mutations and EGFR tyrosine kinase inhibitors.